Editas FY26 Q2 net loss narrows to $18.2 million; revenue more than doubled to $11.9 million - EDIT News | RalliesEditas FY26 Q2 net loss narrows to $18.2 million; revenue more than doubled to $11.9 million
E
EDIT• Pipeline update
- EDIT-401 remains on track for an Australia CTN submission this month; Phase 1/2 data update expected in Q1 2027.
Quarterly results
- Editas Medicine posted a Q2 2026 net loss of USD 18.2 million, narrowing from USD 53.2 million a year earlier.
- Revenue climbed to USD 11.9 million from USD 3.6 million, driven by deferred revenue recognized after certain BMS opt-in rights expired.
- R&D expense rose to USD 20.2 million from USD 16.2 million, while G&A expense fell to USD 11.6 million from USD 12.9 million.
Cash position and runway
- Cash and cash equivalents increased to USD 211.6 million at June 30 from USD 146.6 million at Dec. 31; cash runway guided into H2 2028.
